IPREX Respirator 20ml Soln.

Overview

Iprex Respirator Solution contains Ipratropium Bromide 250 mcg/ml, an anticholinergic bronchodilator for use via nebulisation. It is indicated for the treatment of reversible bronchospasm associated with Chronic Obstructive Pulmonary Disease (COPD), and when used concomitantly with inhaled beta-2 agonists, for treatment of reversible airway obstruction in acute and chronic asthma. Ipratropium Bromide works by inhibiting vagal reflexes through antagonism of acetylcholine at muscarinic receptors on bronchial smooth muscle, preventing bronchoconstriction and promoting bronchodilation. Iprex Nebuliser Solution is supplied as a 20 ml multi-dose bottle containing 250 mcg/ml of Ipratropium Bromide.

Dosage and Administration

Adults and children over 12 years: 250–500 micrograms (1 ml or 2 ml) 3 to 4 times daily via nebuliser. For acute bronchospasm: 500 micrograms/2 ml. Daily doses exceeding 2 mg should only be given under medical supervision.

Children 6–12 years: 250 micrograms (1 ml) up to a total daily dose of 1 mg (4 ml). Time interval between doses to be determined by the physician.

Children 0–5 years (acute asthma only): 125–250 micrograms (0.5–1 ml) up to a total daily dose of 1 mg (4 ml). Administer no more frequently than every 6 hours. Repeated doses can be given until the patient is stable.

The nebuliser solution may be combined with a short-acting beta-2 agonist in the same nebuliser chamber. Use immediately after mixing; discard any unused solution. If dilution is required, use only sterile sodium chloride 0.9% solution. Not for oral or parenteral administration.

Interaction

Iprex has been used concomitantly with sympathomimetic bronchodilators, methylxanthines, steroids, and cromolyn sodium without adverse drug reactions. No fully evaluated interaction studies with respect to combined effectiveness are available.

Contraindications

Contraindicated in patients with known hypersensitivity to Atropine or its derivatives, or to any component of the formulation.

Side Effects

Common side effects of the nebuliser solution include headache, dizziness, cough, inhalation-induced bronchospasm, dryness of the mouth, and vomiting. Uncommon effects include urticaria, tachycardia, skin rash, and pruritus. Rare effects include anaphylactic reaction, eye pain, mydriasis, increased intraocular pressure, palpitations, atrial fibrillation, and nausea. Isolated reports of ocular complications (mydriasis, increased intraocular pressure, narrow-angle glaucoma, eye pain) have been noted when aerosolised solution contacted the eyes during nebulisation.

Pregnancy and Lactation

The safety of Ipratropium Bromide Nebuliser Solution during human pregnancy has not been established. Benefits must be weighed against possible hazards to the foetus. It is unknown whether Ipratropium Bromide is excreted in breast milk; caution is advised during nursing.

Precautions and Warnings

Initiation of nebuliser therapy should be under close medical supervision. Use with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, bladder-outflow obstruction, or cystic fibrosis. Care must be taken not to allow solution or mist to enter the eyes — administer via a mouthpiece wherever possible. If a nebuliser mask is used, it must fit properly. Do not store above 25°C. As the product contains no preservative, use a fresh ampoule for each dose and discard any remaining solution after use.

Storage Conditions

Do not store above 25°C. Keep the ampoule/bottle in the outer carton, away from light. As the product contains no preservative, open immediately before use and discard unused solution. Keep out of the reach of children.

Frequently Asked Questions

Q: What is Iprex Respirator Solution used for?
Iprex Respirator Solution (Ipratropium Bromide 250 mcg/ml) is used via nebulisation to treat and relieve bronchospasm in COPD (chronic bronchitis, emphysema) and asthma. It works by blocking muscarinic receptors in the airways, causing smooth muscle relaxation and bronchodilation. It is particularly useful in COPD management and for patients who cannot coordinate a metered-dose inhaler effectively.

Q: Can Iprex Respirator Solution be mixed with other nebuliser medications?
Yes — Iprex Nebuliser Solution can be mixed with a short-acting beta-2 agonist (such as salbutamol) in the same nebuliser chamber, providing a combined bronchodilator effect that is often more effective than either agent alone. However, use the mixture immediately after preparation and discard any leftover solution. Do not mix with other medications without physician or pharmacist guidance.